Gaurav Mendiratta, Kodye Abbott, Yao-Cheng Li, Jingting Yu, Peter Carlip, Melinda Tong, Jianfeng Huang, Maxim N Shokhirev, Thomas McFall, Geoffrey M Wahl and 1 more
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Gaurav MendirattaIntegrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California, United States of America.ORCID 0000-0001-5091-348X
Kodye AbbottDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Yao-Cheng LiGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California, United States of America.
Jingting YuThe Razavi Newman Integrative Genomics and Bioinformatics Core (IGC), Salk Institute for Biological Studies, La Jolla, California, United States of America.
Peter CarlipDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0009-0003-8257-2001
Melinda TongIntegrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California, United States of America.
Jianfeng HuangIntegrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California, United States of America.
Maxim N ShokhirevThe Razavi Newman Integrative Genomics and Bioinformatics Core (IGC), Salk Institute for Biological Studies, La Jolla, California, United States of America.
Thomas McFallDepartment of Biochemistry and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
Geoffrey M WahlGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California, United States of America.
Edward C StitesDepartment of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0002-3783-7336
Funding
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapyP01AG073084 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS, GERALD SHADEL · 2021 to 2026
$13.6M
Salk Institute Cancer Training GrantT32CA009370 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Diana Clare Hargreaves, Jan Karlseder · 1986 to 2026
$8.6M
Combining single cell approaches and a developmental perspective to discover stem cell control circuits and the cellular and molecular bases of cancer heterogeneityR35CA197687 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI WAHL, GEOFFREY MYLES · 2015 to 2021
$7.8M
San Diego Nathan Shock CenterP30AG068635 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI SHADEL, GERALD · 2020 to 2024
$6.0M
The Discovery of Human Peptide Encoding GenesR01GM102491 · NIGMS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI O'SHEA, CLODAGH, SAGHATELIAN, ALAN · 2012 to 2025
$5.5M
Systems Approaches for Opening Therapeutic WindowsDP2AT011327 · NCCIH · YALE UNIVERSITY · PI STITES, EDWARD C. · 2020 to 2020
$2.6M
Systems Biology of RAS and RAF Oncogenes and Personalized MedicineK22CA216318 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI STITES, EDWARD C. · 2017 to 2019
RAF inhibitor "paradoxical activation" (PA) is a phenomenon where RAF kinase inhibitors increase RAF kinase signaling. Through mathematical modeling and experimental data analysis, we recently demonstrated that the combination of conformational autoinhibition (CA) with the disruption of CA by RAF inhibitors plays an important role in PA. 14-3-3 proteins are known to modulate RAF CA and RAF dimerization. We here extend our mathematical model to include both roles of 14-3-3 proteins, and we derive rigorous analytical expressions of RAF signal regulation as modulated by 14-3-3 proteins. We then use the model to investigate how 14-3-3 proteins may modulate PA. We mathematically show 14-3-3 protein stabilization of the autoinhibited form of RAF should potentiate PA, while 14-3-3 protein stabilization of the active RAF dimer should reduce PA. Our analysis suggests that the net-effect will often be a potentiation of PA, and that 14-3-3 proteins may be capable of inducing PA for RAF inhibitors that normally show little to no PA. We test model-based insights experimentally with two different approaches: forced increases in 14-3-3 expression (which we find amplifies PA) and evolved resistance assays (which suggest increased 14-3-3 expression may contribute to resistance to RAF inhibitors). Overall, this work supports a role for 14-3-3 in modulating RAF-inhibitor mediated paradoxical activation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mathematical modeling suggests 14-3-3 proteins modulate RAF paradoxical activation. · full record | OpenQuestion